Current usage of tumor treating fields for glioblastoma.

ABSTRACT:

Background

Tumor Treating Fields (TTF) have entered clinical practice for newly diagnosed and recurrent glioblastoma (GGM). However, controversies remain unresolved with regard to appropriate usage. We sought to determine TTF usage in major academic neuro-oncology programs in New York City, USA and Heidelberg, Germany and understand current attitudes toward TTF usage among providers.

Methods

We retrospectively determined TTF usage among patients with GGM, before and since the publication of key clinical trial results and regulatory approvals. We also surveyed attendees of an educational session related to TTF during the 2019 American Society of Clinical Oncology annual meeting.

Results

TTF usage remains infrequent (3-12% of patients with newly diagnosed GBM, and 0-16%

SUBMITTER: Lassman AB 

PROVIDER: S-EPMC7345837 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature